DUPONT CAPITAL MANAGEMENT CORP - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 243 filers reported holding HAEMONETICS CORP in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.

Quarter-by-quarter ownership
DUPONT CAPITAL MANAGEMENT CORP ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q4 2022$157,536
-67.3%
2,003
-69.3%
0.01%
-75.9%
Q3 2022$482,000
-23.1%
6,514
-32.3%
0.03%0.0%
Q2 2022$627,000
+97.2%
9,625
+91.2%
0.03%
+123.1%
Q1 2022$318,000
+9.3%
5,034
-8.1%
0.01%
+30.0%
Q4 2021$291,000
-66.2%
5,480
-55.1%
0.01%
-63.0%
Q3 2021$862,000
-7.2%
12,218
-12.3%
0.03%
+22.7%
Q2 2021$929,000
+128.8%
13,935
+280.8%
0.02%
+120.0%
Q1 2021$406,000
+140.2%
3,659
+157.0%
0.01%
+150.0%
Q4 2020$169,000
+482.8%
1,424
+330.2%
0.00%
+300.0%
Q3 2020$29,000
-98.5%
331
-98.5%
0.00%
-97.7%
Q2 2020$1,999,000
-21.1%
22,324
-12.1%
0.04%
-26.7%
Q1 2020$2,532,000
-44.3%
25,409
-35.7%
0.06%
-41.2%
Q4 2019$4,543,000
+8.2%
39,537
+18.8%
0.10%
+6.2%
Q3 2019$4,197,000
+48.1%
33,270
+41.3%
0.10%
+47.7%
Q2 2019$2,834,000
+26.0%
23,550
-8.5%
0.06%
+27.5%
Q1 2019$2,250,000
-1.4%
25,725
+12.8%
0.05%
-8.9%
Q4 2018$2,281,000
-24.2%
22,800
-13.2%
0.06%
-15.2%
Q3 2018$3,011,000
-16.8%
26,282
-34.9%
0.07%
-23.3%
Q2 2018$3,619,000
+177.5%
40,353
+126.5%
0.09%
+168.8%
Q1 2018$1,304,000
-11.8%
17,818
-30.0%
0.03%
-5.9%
Q4 2017$1,479,00025,4570.03%
Other shareholders
HAEMONETICS CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Millrace Asset Group, Inc. 19,264$1,7262.13%
Parkman Healthcare Partners LLC 88,962$7,969,2161.46%
HEARTLAND ADVISORS INC 256,414$24,435,2741.37%
Riverwater Partners LLC 15,553$1,393,2381.27%
KINGDON CAPITAL MANAGEMENT, L.L.C. 111,100$9,952,3381.15%
Lisanti Capital Growth, LLC 78,425$7,025,3121.11%
Aristotle Capital Boston, LLC 311,666$27,919,0540.90%
ROYCE & ASSOCIATES LP 947,550$84,881,5290.86%
CHASE INVESTMENT COUNSEL CORP 18,770$1,6810.84%
Virtus Investment Advisers, Inc. 13,662$1,223,8420.83%
View complete list of HAEMONETICS CORP shareholders